Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Thiazinamium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.59 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.59 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.59 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.59 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.56 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.59 |
| ▸ | HTR1A | P08908 | 4/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.59 |
| ▸ | DRD1 | P21728 | 4/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.59 |
| ▸ | DRD3 | P35462 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiazinamium SCHEMBL4425937 | 0.98 | PTGS1 (0.65) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL11619269 | 0.97 | PTGS1 (0.63) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL29856760 | 0.97 | PTGS1 (0.63) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL11617990 | 0.97 | PTGS1 (0.63) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL11613970 | 0.90 | PTGS1 (0.55) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| SCHEMBL13257618 | 0.85 | PTGS1 (0.61) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| SCHEMBL3329470 | 0.85 | PTGS1 (0.61) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL29714760 | 0.85 | PTGS1 (0.50) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL29040 | 0.85 | PTGS1 (0.50) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Bromide SCHEMBL22588368 | 0.84 | PTGS1 (0.59) | PTGS1PTGS2CYP2D6CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-4097596-A | BRONCHODILATOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-06-27 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2000040604-A2 | METHODS AND COMPOSITIONS FOR MODULATING CYTOKINE RELEASE BY αEβ7-EXPRESSING CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-1999036570-A2 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE INC (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-4097596-A | BRONCHODILATOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | CHRM2 158/4885CHRM1 312/4885SLC6A2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.